Immuneering Corporation

Immuneering Corporation

Immuneering Corporation, with its slogan "Better Medicines Through Signaling Dynamics," is a biopharmaceutical company founded in 2008 in the United States. The company is dedicated to improving patient outcomes for various debilitating oncologic and neurologic diseases. Immuneering leverages its extensive expertise in translational bioinformatics, spanning over a decade, to gain insights into drug mechanisms of action and patient treatment responses.

One of the company's significant achievements is the development of a disease-agnostic platform that harnesses human data, novel biology and chemistry, and translational planning to advance its proprietary pipeline. Immuneering's current focus in oncology is on developing potential treatments for solid tumors caused by mutations of oncologic signaling pathways, particularly the MAPK pathway.

The company's lead product candidate, IMM-1-104, targets RAS mutant tumors by disrupting KSR as a highly selective dual-MEK inhibitor. Additionally, Immuneering has six other oncology programs and two neuroscience programs in the discovery stage, demonstrating its commitment to a diverse range of therapeutic areas.

Notably, Immuneering secured a substantial $30.00M post-IPO equity investment on 01 April 2023, signaling confidence from investors in the company's innovative approach and promising pipeline.

For additional information, please visit www.immuneering.com.

The absence of specific investors for the last investment round indicates an opportunity for potential investors intrigued by Immuneering's groundbreaking work and its future prospects in the biotechnology and pharmaceutical industries.